Skip to main content
An official website of the United States government
Program Official
Principal Investigator
Samuel J. Milanovich
Awardee Organization

Sanford Research/Usd
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Sanford Community Cancer Program of the North Central Plains (NCORP)

Sanford Research, a non-profit research institution within Sanford Health, is dedicated to improving cancer outcomes through scientific discovery, clinical innovation, and broad community engagement. Serving one of the largest rural healthcare networks in the United States, Sanford Research is uniquely positioned to enhance the mission of the NCI Community Oncology Research Program (NCORP) by expanding access to cutting-edge cancer clinical trials, prevention strategies, and cancer care delivery research across rural, urban, and geographically dispersed populations.  Sanford Health spans over 250,000 square miles across the Upper Midwest, including North Dakota, South Dakota, Minnesota, Iowa, and rural communities in Montana and Nebraska. With more than 80 oncology providers across a network of more than 50 affiliated sites, Sanford has a well-established infrastructure for clinical trial implementation, regulatory compliance, and patient navigation. Sanford Research integrates seamlessly with Sanford’s clinical operations to streamline the activation, accrual, and management of NCI-sponsored trials.  Sanford has demonstrated strong performance in enrolling patients in oncology trials.  Through continued participation in NCORP, Sanford Research will build upon its existing foundation to expand research in cancer prevention and control, survivorship, and cancer care delivery science. Special emphasis will be placed on recruiting participants from rural populations to ensure broader representation in cancer research. Sanford’s multidisciplinary research teams—including epidemiologists, behavioral scientists, and clinical investigators—are prepared to contribute to NCORP’s national priorities while supporting meaningful local impact through community partnerships, patient-centered outreach, and data-driven care improvements.  Through this collaboration, Sanford Research aims to drive innovation and access in oncology care—furthering the NCORP mission and improving outcomes for patients in our communities through clinical research.

Publications

  • Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas. 2021 Feb;144:37-44. Epub 2020 Dec 2. PMID: 33358206
  • Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood cancer journal. 2020 May 11;10(5):53. PMID: 32393732
  • Barton DL, Atherton PJ, Satele DV, Qin R, Dakhil S, Pipe T, Hobday T, Fee-Schroeder K, Loprinzi CL. A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020 Dec;28(12):6085-6094. Epub 2020 Apr 19. PMID: 32307658
  • Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC. Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. Journal of neuro-oncology. 2010 Aug;99(1):73-80. Epub 2010 Jan 9. PMID: 20063115
  • Leal TA, Wang Y, Dowlati A, Chay CH, Chen Y, Mohindra AR, Razaq M, Ajuja HG, Liu J, King DM, Sumey CJ, Ramalingam SS. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Cancer. 2025 Jun 15;131(12):e35938. PMID: 40526078
  • McCleary NJ, Hubbard J, Mahoney MR, Meyerhardt JA, Sargent D, Venook A, Grothey A. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). Journal of geriatric oncology. 2018 Jan;9(1):24-31. Epub 2017 Sep 13. PMID: 28917648
  • McWilliams RR, Allred JB, Slostad JA, Katipamula R, Dronca RS, Rumilla KM, Erickson LA, Bryce AH, Joseph RW, Kottschade LA, King DM, Leitch JM, Markovic SN. NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. Cancer. 2018 Feb 1;124(3):537-545. Epub 2017 Oct 17. PMID: 29044496
  • Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). The oncologist. 2019 May;24(5):589-e160. Epub 2019 Jan 24. PMID: 30679315
  • Dronca RS, Allred JB, Perez DG, Nevala WK, Lieser EA, Thompson M, Maples WJ, Creagan ET, Pockaj BA, Kaur JS, Moore TD, Marchello BT, Markovic SN. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. American journal of clinical oncology. 2014 Aug;37(4):369-76. PMID: 23357973
  • Breen WG, Dixon JG, Anderson SK, Sarkaria JN, Brown PD, Yan ES, Kizilbash S, Galanis E, Anderson D, Tran D, Mazurczak M, Johnson DR, Geoffroy FJ, Leinweber C, Laack NN. Final Report on NCCTG N0877 (Alliance): A Phase II Randomized, Placebo-Controlled Trial of Chemoradiotherapy with or without Dasatinib for Glioblastoma. Neuro-oncology. 2025 Jun 28. Epub 2025 Jun 28. PMID: 40579995
  • Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause (New York, N.Y.). 2015 Jun;22(6):627-32. PMID: 25423327
  • Parikh K, Mandrekar SJ, Allen-Ziegler K, Esplin B, Tan AD, Marchello B, Adjei AA, Molina JR. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). The oncologist. 2020 Jun;25(6):523-531. Epub 2019 Dec 24. PMID: 31872928
  • Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB, North Central Cancer Treatment Group. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leukemia & lymphoma. 2008 Jun;49(6):1074-80. PMID: 18569634
  • Schild SE, Hillman SL, Tan AD, Ross HJ, McGinnis WL, Garces YA, Graham DL, Adjei AA, Jett JR, Mayo Clinic North Central Cancer Treatment Group. Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Apr;12(4):697-703. Epub 2017 Jan 12. PMID: 28089762
  • Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS, ECOG-ACRIN 1512 Investigators. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. The Lancet. Oncology. 2016 Dec;17(12):1661-1671. Epub 2016 Nov 4. PMID: 27825638
  • Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. The New England journal of medicine. 2016 Jul 14;375(2):134-42. PMID: 27410922
  • Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Ginos B, Heying E, Wu TT, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, Alberts SR. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). European journal of cancer (Oxford, England : 1990). 2021 Jun;150:214-223. Epub 2021 Apr 29. PMID: 33934058
  • Halfdanarson TR, Foster NR, Kim GP, Haddock MG, Dakhil SR, Behrens RJ, Alberts SR. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. The oncologist. 2022 Jul 5;27(7):534-e546. PMID: 35285484
  • Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3;317(1):48-58. PMID: 28030702
  • Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). Acta haematologica. 2019;142(4):224-232. Epub 2019 Jul 23. PMID: 31336367
  • Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019 Nov 1;125(21):3790-3800. Epub 2019 Jul 10. PMID: 31290996
  • Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of neuro-oncology. 2019 Jul;143(3):573-581. Epub 2019 May 22. PMID: 31119479
  • Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017 Dec 1;123(23):4653-4662. Epub 2017 Aug 7. PMID: 28786105
  • McWilliams RR, Foster NR, Mahoney MR, Smyrk TC, Murray JA, Ames MM, Horvath LE, Schneider DJ, Hobday TJ, Jatoi A, Meyers JP, Goetz MP. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 2017 Sep 15;123(18):3494-3501. Epub 2017 May 10. PMID: 28493308
  • Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (London, England). 2017 Feb 4;389(10068):519-527. Epub 2016 Dec 23. PMID: 28017406